GMED
Globus Medical, Inc.
GMED's fundamentals are strong and it looks cheap: trading at 18x earnings, less than half its usual 41x. Analysts expect earnings growth.
GMED Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Strong | |
| Strong | |
| Strong |
GMED's profitability, cash flow and balance sheet are currently strong, and its revenue is stable.
GMED PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 14x | $72.30 | — |
| Current | 18x | $72.30 | — |
| Cheap | 26x | $106 | +46% |
| Fair | 41x | $166 | +129% |
| Expensive | 70x | $283 | +291% |
Historical ranges are pointers, not guarantees.
GMED's PE is in its cheap range at 18x. If earnings grow as analysts expect, today's price would be 14x next year's earnings.
GMED Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect GMED's earnings to grow and its profitability to improve, with its revenue holding steady.
GMED Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.18 | +28% |
| Q3 2026 | $4.05 | +31% |
| Q2 2026 | $3.89 | +50% |
| Q1 2026 | $4.28 | +219% |
| Q4 2025 | $3.92 | +423% |
| Q3 2025 | $3.10 | +349% |
| Q2 2025 | $2.60 | +713% |
| Q1 2025 | $1.34 | +103% |
| Q4 2024 | $0.75 | -37% |
GMED earned $4.05 per share over the past year, up 31% from the year before.
GMED Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $763.7M | -0.7% |
| Q2 2026 | $789.6M | +5.9% |
| Q1 2026 | $759.9M | +27% |
| Q4 2025 | $826.4M | +26% |
| Q3 2025 | $769M | +23% |
| Q2 2025 | $745.3M | +18% |
| Q1 2025 | $598.1M | -1.4% |
| Q4 2024 | $657.3M | +6.6% |
GMED's revenue is growing: $764M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +5.4 points |
| Q2 2026 | 23% | +13 points |
| Q1 2026 | 20% | +3.6 points |
| Q4 2025 | 20% | +11 points |
| Q3 2025 | 18% | +10 points |
| Q2 2025 | 10% | +2.3 points |
| Q1 2025 | 16% | +15 points |
| Q4 2024 | 9.2% | +7.5 points |
GMED's operating margin was 23% last quarter, up 5.4 points from the same quarter a year ago.
GMED Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $224.8M | +5.1% |
| Q2 2026 | $176.6M | +464% |
| Q1 2026 | $162.7M | +15% |
| Q4 2025 | $202.4M | +4.7% |
| Q3 2025 | $213.9M | +32% |
| Q2 2025 | $31.3M | +18% |
| Q1 2025 | $141.2M | +493% |
| Q4 2024 | $193.2M | +136% |
GMED's free cash flow has been positive every quarter for seven years: $767M over the past year, up 32% from the year before.
GMED Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -1.4M shares |
| 1 year | +0.5% | +623K shares |
| 3 years | +18% | +20.8M shares |
| 5 years | +30% | +31.6M shares |
| Available history | +33% | +34M shares |
GMED has 136M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $142.9M |
| Q2 2026 | $136.1M |
| Q1 2026 | — |
| Q4 2025 | $45M |
| Q3 2025 | $40M |
| Q2 2025 | $25M |
| Q1 2025 | $190.5M |
| Q4 2024 | $1M |
GMED spent $324M buying back its own shares over the past year, up 26% from the year before.
GMED Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.5x | Net Cash |
| Q2 2026 | -0.6x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.4x | Net Cash |
| Q1 2025 | -0.9x | Net Cash |
| Q4 2024 | -1.9x | Net Cash |
GMED has more cash than debt.
GMED Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.8 | Neutral |
| Stochastic | 15.8 | Oversold |
GMED's weekly RSI is 42 (neutral) and its Stochastic is 16 (oversold).
GMED PE vs Healthcare Sector
| Metric | GMED | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 31% below |
| PE % | 0 | 29 | 29 pts below |
GMED is trading at 18x earnings, a 31% discount to the Healthcare sector's median of 26x.
GMED Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $75.5 | 4.3% below |
| 20 week MA | $78.0 | 7.3% below |
| 50 week MA | $83.6 | 14% below |
| 100 week MA | $76.5 | 5.5% below |
| 200 week MA | $68.5 | 5.6% above |
GMED has fallen below most of its moving averages, though it's still 5.6% above its 200-week average.
GMED Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $65.3 | +11% |
| 2021 | $65.3 | $72.2 | +11% |
| 2022 | $72.2 | $73.9 | +2.3% |
| 2023 | $73.9 | $53.3 | -28% |
| 2024 | $53.3 | $83.6 | +57% |
| 2025 | $83.6 | $88.4 | +5.8% |
| 2026 YTD | $88.4 | $72.3 | -18% |
GMED has finished higher in five of the last six years. It's down 18% so far in 2026.